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Abstract
Background: Median survival in patients with unresectable locally advanced pancreatic cancer lies in
the range of 9–15 months. Radiofrequency ablation (RFA) may prolong survival, but data on its safety and
efficacy are scarce.
Methods: A systematic literature search was performed in PubMed, EMBASE and the Cochrane Library
with the syntax ‘(radiofrequency OR RFA) AND (pancreas OR pancreatic)’ for studies published until 1
January 2012. In addition, a search of the proceedings of conferences on pancreatic disease that took
place during 2009–2011 was performed. Studies with fewer than five patients were excluded as they were
considered to be case reports. The primary endpoint was survival. Secondary endpoints included
morbidity and mortality.
Results: Five studies involving a total of 158 patients with pancreatic cancer treated with RFA fulfilled the
eligibility criteria. These studies reported median survival after RFA of 3–33 months, morbidity related to
RFA of 4–37%, mortality of 0–19% and overall morbidity of 10–43%. Pooling of data was not appropriate
as the study populations and reported outcomes were heterogeneous. Crucial safety aspects included
ensuring a maximum RFA tip temperature of < 90 °C and ensuring minimum distances between the RFA
probe and surrounding structures.
Conclusions: Radiofrequency ablation seems to be feasible and safe when it is used with the correct
temperature and at an appropriate distance from vital structures. It appears to have a positive impact on
survival. Multicentre randomized trials are necessary to determine the true effect size of RFA and to
minimize the impacts of selection and publication biases.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related
death in Western societies.1 At the time of diagnosis, 20% of
patients present with a resectable tumour, 40% with an unre-
sectable locally advanced tumour and 40% with metastatic
disease.2,3 After resection, 5-year overall survival rates are
17–24%.4 Median survival in patients with unresectable locally
advanced pancreatic cancer lies in the range of 9–15 months,
whereas in patients with distant metastasis, median survival is
6 months.4,5
In patients with unresectable locally advanced pancreatic
cancer, chemotherapy and radiotherapy provide minimal survival
benefits. Gemcitabine gives a modest survival benefit of 3 months
and trials on chemoradiation therapy show a marginal effect.6,7
Therefore, there is a clear need for novel, effective therapies in
these patients.
Radiofrequency ablation (RFA) has been proposed as a new
treatment option for unresectable locally advanced pancreatic
cancer. This treatment may lead to prolonged survival, but data on
its safety and efficacy are scarce. The aim of this systematic review
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was to evaluate the safety and survival benefit of RFA in unresect-
able locally advanced pancreatic cancer.
Materials and methods
A systematic literature search was performed in PubMed,
EMBASE and the Cochrane Library for studies published in
English up to 1 January 2012. In addition, a search of the proceed-
ings of conferences on pancreatic disease (European Pancreatic
Club, Pancreas Club, International Hepato-Pancreato-Biliary
Association) in 2009, 2010 and 2011 was performed. Search terms
were (radiofrequency OR RFA) AND (pancreas OR pancreatic),
and were restricted to the title, abstract and keywords. All titles
and abstracts of studies identified in the initial search were
screened to identify those reporting on patients with unresectable
locally advanced pancreatic cancer undergoing RFA. Subse-
quently, full-text papers of the selected studies were screened inde-
pendently by two authors to assess eligibility.
Inclusion criteria required the study population to consist of
patients with unresectable locally advanced pancreatic cancer
defined as stage III according to the American Joint Committee
on Cancer (AJCC) tumour–node–metastasis (TNM) classifica-
tion, who underwent a surgical RFA procedure. Exclusion crite-
ria ruled out any study with a very small cohort (fewer than five
patients) and any study reporting on RFA of tumours other than
pancreatic adenocarcinoma. All cross references were screened
for potentially relevant studies not identified in the initial litera-
ture search.
Data extraction
The following variables were extracted, where available, from the
included articles: number of patients; demographic data (sex and
age); extent of disease; RFA device used; RFA temperature used;
distance of the RFA probe from surrounding structures; number
of RFA probes used; duration of ablation; power at which the
ablation was performed; number of ablations/number of passes of
the probe; whether cooling was used, and the way cooling was
generated.
Results
The results of the literature search are summarized in Fig. 1. Of 29
articles reporting on RFA of unresectable locally advanced pan-
creatic cancer, 22 were excluded for the following reasons: using a
cohort of fewer than five patients (seven studies); using pain as an
outcome rather than survival, morbidity and mortality (one
study); describing a review or overview of the technique (four
studies); describing RFA combined with intraoperative 125-
iodine seed implantation influencing outcome (one study);
describing tumours other than pancreatic adenocarcinoma (four
studies); describing a non-surgical RFA procedure (one study);
being written in a language other than English (three studies), and
comprising a letter to the editor (one study). The remaining seven
studies were considered eligible. However, of these seven
studies,8–10 three reported results in overlapping cohorts. For this
reason, two studies were excluded although they had been
appraised as eligible.8–10,12–15 The remaining five studies were
included in the present review.8–15 Four studies were prospective
cohort studies10,12,14,15 and one study was a retrospective cohort
study.13 The characteristics of the five included studies are sum-
marized in Table 1.
Patient characteristics
The five studies included a total of 158 patients who underwent
RFA for unresectable ductal pancreatic adenocarcinoma. The
number of patients per study ranged from 10 to 100. Patient
characteristics are summarized in Table 2. The male : female ratio
in the pooled data was 1.3 : 1. Ages ranged between 45 years and
72 years. Radiofrequency ablation was performed in 138 patients
with stage III locally advanced pancreatic cancer and in 20
patients with metastatic pancreatic disease.
Characteristics of RFA
The characteristics of the 158 RFA procedures are summarized in
Table 1. In two studies,13,14 an RFA device manufactured by Radi-
onics, Inc. (Burlington, MA, USA) was used. One study12 used a
generator manufactured by Berchtold GmbH & Co. KG (Tuttlin-
gen, Germany), one study15 used a generator manufactured by
Omron Co. Ltd (Kyoto, Japan) and one study10 used a Generator
1500X manufactured by Rita Medical Systems, Inc. (Mountain
View, CA, USA). Four studies10.13–15 reported the RFA temperature
used; in two studies,10,13 a temperature of 90 °C was used during
the whole RFA procedure. In one study,14 RFA was performed for
12 min at a temperature of 30 °C and for 1 min at a temperature
of 90 °C. In one study,15 an RFA temperature of 50 °C was used
during the whole procedure. Only two studies10,14 reported the
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distance of the RFA probe from surrounding structures. In one
study15 the distance of the RFA probe was 10 mm from the duo-
denum and 5 mm from the portomesenteric vessels. In the other
study,10 RFA was performed only at the site of the portomesenteric
vessels at a distance of 5 mm. The duration of ablation was
reported in four studies10,13–15 and varied in all of them, ranging
from 5 min to 15 min. The power at which RFA was performed
was reported in four studies10,12,14,15 and also varied across
studies,10,13–15 ranging from 40 W to 500 W. Four studies reported
the number of passes of the RFA probe, which ranged from 1 to
15. The use of cooling was reported in two studies.10,13 In one
study,10 the RFA area was cooled with cold saline administered
directly with a syringe, a cold wet gauze was placed over the
inferior vena cava to protect it from heat and the duodenum was
perfused continuously with cold saline solution through a
nasogastric tube placed in the second part of the duodenum. In
the other study,10 only the ablation area was cooled with cold
saline.
Morbidity and mortality
The outcomes as reported in the studies are shown in Table 3. Rates
of RFA-related morbidity ranged from 10% to 37%. Complications
related to RFA included pancreatic fistulae, portal vein thrombosis,
gastrointestinal bleeding and acute pancreatitis. Rates of RFA-
related mortality ranged from 0% to 19%. The RFA-related com-
plications that resulted in patient deaths included gastrointestinal
bleeding and sepsis. Rates of overall complications ranged from
10% to 43%. The types of complication reported varied widely and
included pneumonia, peritoneal cavity abscess, acute renal failure,
transient ascites, hepatic insufficiency, pseudomembrane colitis,
haemoperitoneum, abdominal fluid collection, gastric bypass
fistula, gastric ulcer and choledocholithiasis.
Survival
One of the five studies14 included did not report survival after
RFA. Of the remaining four studies, three10,13,15 reported median
survival and one12 reported the range of survival.
Table 1 Study characteristics
Authors Year Patients,
n
Study design RFA
device
RFA
temperature
Distance of
RFA probea,
mm
RFA
duration,
min
Power Ablations,
n
Cooling
with
saline
Girelli et al.10 2011 100 Prospective cohort Rita 90 °C 5–10 5–10 250 1–2 Area
Duodenum,
vena cava
Singh et al.12 2011 10 Prospective cohort Berchtold – – – 40–60 – –
Spiliotis et al.13 2007 12 Retrospective cohort Radionics 90 °C – 5–7 – 1–3 Area
Wu et al.14 2006 16 Prospective cohort Radionics 30–90 °C 5 12 and 1b 0–200 2–5 –
Matsui et al.15 2000 20 Prospective cohort Omron 50 °C – 15 500 1–15 –
aDistance of RFA probe from duodenum or portomesenteric vessels.
b12 min at 30 °C and 1 min at 90 °C.
RFA, radiofrequency ablation.
Table 2 Patient characteristics
Authors Year Patients, n Male/female, n Age, years Extent of disease, n
Locally advanced Metastatic
Girelli et al.10 2011 100 55/45 Median: 64 100 –
Singh et al.12 2011 10 – Range: 45–72 10 –
Spiliotis et al.13 2007 12 6/6 Median: 66 8 4
Wu et al.14 2006 16 10/6 Median: 67 11 5
Matsui et al.15 2000 20 12/8 Median: 59 9 11
Table 3 Radiofrequency ablation (RFA)-related morbidity, mortality and survival after RFA
Authors Year Patients,
n
Extent of disease, n Bypass
surgery,
n
Overall
complications
RFA-related
morbidity
RFA-related
mortality
Median
survival,
monthsLocally advanced Metastatic
Girelli et al.10 2011 100 100 – 53 26% 15% 3% 20
Singh et al.12 2011 10 10 – 0 10% 10% 0% 9–36
Spiliotis et al.13 2007 12 8 4 12 25% 16% 0% 33
Wu et al.14 2006 16 11 5 2 43% 37% 19% –
Matsui et al.15 2000 20 9 11 – 10% 10% 5% 3
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Median survival after RFA in patients with stage III unresect-
able locally advanced pancreatic cancer ranged from 20 months to
33 months. The study12 that reported survival lengths rather than
median survival cited a range of 9–36 months. One study15
reported median survival in patients with unresectable locally
advanced pancreatic cancer and patients with metastatic pancre-
atic disease without stratifying the data for the respective patient
groups; median survival in this study was 3 months.
Discussion
This study reviewed the safety and survival benefits of RFA of
locally advanced pancreatic cancer. Radiofrequency ablation
appears to be an attractive treatment for locally advanced pancre-
atic cancer. Rates of RFA-related morbidity ranged from 10% to
37%. Rates of RFA-related mortality ranged from 0% to 19%.
Median survival after RFA in patients with stage III locally
advanced pancreatic cancer lay in the range of 20–33 months. One
study12 did not report median survival, but cited a range of sur-
vival of 9–36 months. One study15 reported a median survival of
3 months after RFA in a combined sample of patients with unre-
sectable locally advanced pancreatic cancer and patients with
distant metastases.
The study by Wu et al. reported the highest rates of RFA-related
morbidity (38%, 6 of 16 patients) and mortality (19%, 3 of 16
patients).14 In this study, RFA was applied at a distance of 5 mm
from the portomesenteric vessels in 16 patients with locally
advanced pancreatic cancer. Three patients developed a pancreatic
fistula which healed smoothly within 10 days, and three patients
had massive gastrointestinal bleeding as a result of portal vein
thrombosis leading to portal hypertension. The three patients
with massive gastrointestinal bleeding all died, resulting in an
RFA-related mortality rate of 19%. Wu et al. reported that a
minimum distance of 5 mm between the RFA site and major
peripancreatic vessels might not be enough to avoid injury to the
major peripancreatic vessels.14
The largest series, reported by Girelli et al.,10 cited an RFA-related
morbidity of 15% and an RFA-related mortality of 3% in 100
patients with unresectable locally advanced pancreatic cancer.8–11
Girelli et al.8 treated the first 25 patients with RFA at a temperature of
105 °C; at this temperature a high complication rate was seen.8–10
Thereafter, the authors decreased the RFA temperature to 90 °C,
resulting in a significant reduction in the rate of complications,
particularly in rates of mesenteric and portal thrombosis, which
represent typical thermal vein damage,8 and duodenal damage.11 In
the study by Singh et al., no major procedure-related morbidity or
mortality occurred; one patient developed a 2-cm asymptomatic
pseudocyst.12 Spiliotis et al. reported biliary leak after RFA in two
patients.13 Matsui et al. reported cyst formation in two patients and
the development of an abscess in the peritoneal cavity in one patient,
who died of sepsis 21 days after treatment.15
With respect to survival after RFA, the largest series, that
reported by Girelli et al., cited a median survival of 20 months.10
In this study, half of the patients were treated first with RFA and
then with radiochemotherapy or systemic or intra-arterial
chemotherapy or a combination of all of these. In the other half of
the patients, RFA was performed after other primary treatments
(radiochemotherapy or systemic or intra-arterial chemotherapy
or a combination of all of these). This may have led to a selection
bias in some patients who received second-line RFA, who must
have benefited from an earlier treatment in order to receive RFA
later.10 Spiliotis et al. reported a median survival of 33 months
after RFA.13 This study included patients with either stage III or IV
pancreatic cancer. Patients with stage III unresectable locally
advanced pancreatic cancer receiving RFA were all alive at the time
of publication of the study and reached a maximum survival of
38 months.13 Singh et al. reported survival after RFA in the range
of 9–36 months.12 Of the 10 patients included, 8 received post-
RFA chemotherapy.12 Matsui et al. reported a median survival of
3 months.15 However, their series included 11 patients with distant
metastases and 9 patients with unresectable locally advanced pan-
creatic cancer and did not stratify for the two different groups. As
most of these patients had distant metastases, the survival benefit
of RFA in patients with unresectable locally advanced pancreatic
cancer may be underestimated in this study.15
The largest series reported in this review was that of Girelli
et al.10 However, that the other smaller studies reported compara-
ble results is important because it shows that the data were repro-
ducible in other centres. In most studies, rates of RFA-related
morbidity lay in the range of 10–15%, mortality in the range of
0–5% and overall complications in the range of 10–26% (Table 3).
The only exception to this concerns the study by Wu et al., which
showed RFA-related morbidity of 37%, mortality of 19% and
overall complications of 43%.14 Wu et al. demonstrated the
importance of distance as they performed RFA at a distance of
5 mm from major peripancreatic vessels.14 Radiofrequency abla-
tion at this distance resulted in a higher complication rate. With
respect to survival, the results of the studies are similarly compa-
rable, other than those observed in the study by Matsui et al.,15
which included both stage III and stage IV patients. This indicates
that stage IV patients should not be treated with RFA.
The studies reviewed show that there are some important
factors for safety. To prevent the occurrence of complications, the
temperature at which RFA is performed should not exceed a
maximum of 90 °C. Moreover, the distance between the RFA
probe and surrounding structures should be > 5 mm with refer-
ence to the portomesenteric vessels and > 10 mm with reference to
the duodenum. Furthermore, thermal damage to the duodenum
can be prevented by intraluminal duodenal cooling.
Although the studies reviewed here appear to show RFA to be
an attractive treatment option in unresectable locally advanced
pancreatic cancer, this review is subject to some limitations.
Patient populations across the different studies were heterogene-
ous; some studies included patients with either stage III or stage
IV disease, and pre- and post-RFA treatments differed across
studies and within each study. Another limitation refers to the fact
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that the RFA devices and RFA settings (temperature, ablation
duration, power etc.) used in the various studies differed. Because
of these limitations, it was not appropriate to pool the data. Fur-
thermore, there are no randomized controlled trials (RCTs) of
RFA in locally advanced pancreatic cancer.
In conclusion, RFA is a feasible and safe procedure when it is
used with the right setting. Radiofrequency ablation in combina-
tion with chemotherapy and/or radiotherapy may have a positive
impact on survival. A large, multicentre RCT is necessary to deter-
mine the true effect size of RFA and to minimize the impact of
selection and publication biases. Preparations for such a study are
underway.
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